- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Celltrion to Produce Biosimilars in the United States
Drug maker Celltrion has entered into a contract manufacturing organization agreement with Baxter BioPharma Solutions for the production of its biosimilars in the United States.
Korean drug maker Celltrion has entered into a contract manufacturing organization (CMO) agreement with Baxter BioPharma Solutions for the production of its biosimilars in the United States.
Korea Biomedical Review reports that Celltrion’s contract with Baxter is intended to increase the stable supply of biosimilar products for the US marketplace. First to be produced by Baxter is Celltrion’s infliximab (Remicade) biosimilar, which has been approved by the FDA and is marketed as Inflectra in the United States. Celltrion has also submitted Biologics License Applications to the FDA for its rituximab (Rituxan, MabThera) and trastuzumab (Herceptin) biosimilars. If these 2 drugs are approved, Baxter will produce finished products of both biosimilars for the US market.
“With the latest agreement, Celltrion has secured a local drug producer in the [United States], the world’s biggest biopharmaceutical market,” a Celltrion official told The Korea Herald. “The firm expects to meet local demand in a more flexible manner.”
The news that Celltrion will manufacture Inflectra in the US follows the September release of a Form 483 issued by the FDA, noting 12 observations made while the agency inspected Celltion’s Incheon, Republic of Korea facility. Among the concerns identified were issues with vial stoppers, deficient environmental monitoring in aseptic processing areas, and inadequate procedures to prevent microbiological contamination. When the heavily redacted form was released, some analysts suggested that the FDA’s observations could be one factor in explaining the slow uptake of Inflectra in the United States.
Celltrion also recently announced that it has dropped its plans to build a third manufacturing facility in the Republic of Korea amid escalating political tensions with North Korea. Celltrion’s CEO, Seo Jun-jin, told shareholders in a September meeting that the company would make a decision concerning the location of the company’s first overseas factory by early next year.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.
